South San Francisco, CA — December 14th, 2016 — Genentech, a member of the Roche Group, today announced the appointment of Bill Anderson to chief executive officer, effective January 1, 2017.
Anderson, who is also the head of North American commercial operations, has served in a number of key leadership positions at Genentech and Roche over the past 10 years, most recently as head of Global Product Strategy.
Anderson succeeds Ian T. Clark, who will retire at the end of 2016 after 14 years at Genentech. Following the 2009 merger with Roche, Clark drove the successful evolution of Genentech as part of a global organization and has overseen the launch of 15 new medicines.
“We thank Ian for his significant contribution to the company and are pleased to welcome Bill into his new role,” said Daniel O’Day, CEO of Roche’s Pharmaceuticals Division. “Bill is an outstanding leader with a deep understanding of the company and proven expertise in bringing important medicines to people with serious diseases. We are confident that he will nurture Genentech’s unique culture and build upon a legacy of pursuing groundbreaking science to find the next breakthroughs for patients.”
Founded 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.